Search results for

Monica Hyon-Kyong Leeu and In Hwan Kim of Kim & Chang explain how the KFDA's drug re-examination system provides protection for pharmaceutical data in Korea

Biological resources can provide commercial opportunities but their importance for local communities must also be respected. Sunita K Sreedharan of Anand & Anand examines how India has reconciled conflicting demands in this area

Many biotechnology companies are looking hard at their patent portfolios to raise extra revenues. Orrick, Herrington & Sutcliffe's Craig Kaufman and Anne-Marie Dinius reveal how biotech companies can use the law to enhance their ability to enforce their patent rights

In the light of recent cases on the scope of patent protection, William Cook, Peter Meyer and Francis van Velsen of Simmons & Simmons compare the approach of the English, German and Dutch courts

Research into stem cells is leading to new demands on the patent system - and provoking resistance from protesters. Members of FICPI's Biotech Committee Helene Fagerlin, David Bannerman, Lola Bartoszewicz and Danny Huntington survey the latest developments in the US, Europe and elsewhere

Given the richness of Mexico's genetic resources, biopiracy is a serious threat in the country. Osvaldo Amaral of Olivares & Cia examines the existing and proposed legislation to protect local communities

The scope of the experimental use exemption is a vital issue for both research-based and generic pharmaceutical companies. Ina Schreiber and Cyra Nargolwalla of Cabinet Plasseraud examine attempts to harmonize the law in Europe, and compare practice in France, Germany and the UK

According to Section 10(1) of the German Patent Act, a patent has the effect that any third party that does not have the consent of the patentee is prevented from offering or supplying a component relating to an essential element of the invention. According to the recent Flügelrad decision of the German Supreme Court (X ZR 48/03 dated May 4 2004), in assessing what is an essential element of the invention, only components that have a functional interaction with other elements of the patented device can infringe the patent.

Fabrizio Miazzetto examines the issues litigants should consider when bringing proceedings before the new CTM and CD courts in Alicante and discusses the opportunities for rights owners to forum shop in Europe

Patent leader IBM has said that it will provide open access to 500 of its patents to anyone working in the field of open source software.